SCHEMBL3858770

SCHEMBL3858770

COc1ccc2c(c1N1CCN(C)CC1)C=Nc1cc(Cl)ccc1N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 5/20 0.47
DRD2 P14416 4/20 0.47
DRD4 P21917 4/20 0.47
DRD3 P35462 3/20 0.47
HRH4 Q9H3N8 3/20 0.47
HTR1A P08908 2/20 0.47
HTR7 P34969 2/20 0.47
HTR3E A5X5Y0 2/20 0.47
HTR3B O95264 2/20 0.47
HTR3A P46098 2/20 0.47
HTR3D Q70Z44 2/20 0.47
HTR3C Q8WXA8 2/20 0.47
MEN1 O00255 2/20 0.47
MAPK1 P28482 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CACNA1F O60840 1/20 0.47
ABCB11 O95342 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4447696 0.84 CHRM1 (0.52) CHRM1DRD2DRD4DRD3HRH4
SCHEMBL3277971 0.79 DRD2 (0.56) CHRM1DRD2DRD4DRD3HRH4
SCHEMBL30416496 0.79 DRD2 (0.56) CHRM1DRD2DRD4DRD3HRH4
SCHEMBL11535134 0.79 DRD2 (0.50) CHRM1DRD2DRD4DRD3HRH4
Hydrochloric Acid SCHEMBL5445211 0.78 DRD2 (0.55) CHRM1DRD2DRD4DRD3HRH4
SCHEMBL5445017 0.74 CHRM1 (0.49) CHRM1DRD2DRD4DRD3HRH4
SCHEMBL142771 0.68 CHRM1 (0.76) CHRM1DRD2DRD4DRD3HRH4
SCHEMBL4336114 0.67 HTR3E (0.69) DRD2DRD4DRD3HRH4HTR1A
SCHEMBL4202572 0.66 CYP1A2 (0.55) CHRM1DRD2DRD4DRD3HRH4
Clozapine SCHEMBL29112830 0.65 CHRM1 (0.89) CHRM1DRD2DRD4DRD3HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670427-A4 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX INC (US) 2009-01-07 EP disclosed
EP-1670427-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS CombinatoRx, Incorporated (US) 2006-06-21 EP disclosed
WO-2005027839-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2005-03-31 WO disclosed